Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Complete Response” Reg Proposes Deficiency Letter For Withdrawn NDAs

This article was originally published in The Tan Sheet

Executive Summary

The definition of an efficacy supplement, which covers Rx-to-OTC switch applications, would be written into regulation for the first time under a new proposed rule issued by FDA
Advertisement

Related Content

FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
Topical Antimicrobial Proposed Rule Slated For March in “Unified Agenda”
Topical Antimicrobial Proposed Rule Slated For March in “Unified Agenda”
Topical Antimicrobial Proposed Rule Slated For March in “Unified Agenda”
CHPA “approvable”letter comments
CHPA “approvable”letter comments
FDA/industry user fee II proposal would cut review deadline to 10 months from current 12.
FDA/industry user fee II proposal would cut review deadline to 10 months from current 12.

Topics

Advertisement
UsernamePublicRestriction

Register

PS097089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel